 |
|
|
|
  |
|
 |
 |
| | * IMS DDD Lung Surfactant Market Purchases July 1991 through June 2007. On file, Abbott Nutrition Marketing Research. |
| |
| |
| | Please see product disclosure for full prescribing information. |
| |
| | SURVANTA CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. During controlled clinical trials, the most commonly reported adverse experiences were associated with the dosing procedure: Transient bradycardia 11.9% of doses; oxygen desaturation 9.8% of doses; ETT reflux, fewer than 1% of doses. |
|
 |
 |
|
|
